Cannabis-Related Disorders and Toxic Effects
NEJM 389: 2267-2275, Gorelick,D.A., 2023
Restless Legs Syndrome, A Review
JAMA 335:703-714, Winkelmen,J.W. & Wipper, B., 2026
Risk of Dementia in Individuals with Emergency Department Visits or Hospitalizations Due to Cannabis
JAMA Neurol 82:570-579, Myran,D.T.,et al, 2025
Deprescribing in Epilepsy
JAMA Neurol 77:673-674, Terman, S.W.,et al, 2020
Medical Use of Cannabis in 2019
JAMA 322:974-975, Hill, K.P., 2019
Brain Zaps: An Underappreciated Symptom of Antidepressant Discontinuation
Psychiatry.com 2018, Papp, A. & Onton, J.A., 2018
Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents
Stroke 48:1432-1437, Steiner, T.,et al, 2017
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
NEJM 376:2011-2020, Devinsky, O.,et al, 2017
Myasthenia Gravis Exacerbation after Discontinuing Mycophenolate
Neurol 86:1159-1163, Oskarsson, B.,et al, 2016
Varicella-Zoster Virus Infections in Patients Treated with Fingolimod
JAMA Neurol 72:31-39,10, Arvin, A.M.,et al, 2015
Withdrawing Amantadine in Dyskinetic Patients with Parkinson Disease
Neurol 82:300-307, Ory-Magne, F.,et al, 2014
Drug Treatment of Epilepsy in Adults
BMJ 348:g2546, Schmidt, D. & Schachter, S.C., 2014
Should Doctors Prescribe Cannabinoids?
BMJ 348:g2737, Farrell, M.,et al, 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
Statin Therapy should not be Discontinued in Patients with Intracerebral Hemorrhage
Stroke 44:2060-2061,2062, Bustamante, A. & Montaner, J., 2013
Statin Therapy should be Discontinued in Patients with Intracerebral Hemorrhage
Stroke 44:2058-2059,2062, Goldstein, L., 2013
Serotonin Syndrome Associated with Clozapine Withdrawal
JAMA Neurol 70:1054-1055, Stevenson, E.,et al, 2013
Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012
Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Arch Neurol 68:186-191, Miravalle,A.,et al, 2011
Dopamine Agonist Withdrawal Syndrome in Parkinson Disease
Arch Neurol 67:58-63, Rabinak,C. &Nirenberg,M., 2010
Neuromuscular Symptoms and Elevated Creatine Kinase After Statin Withdrawal
NEJM 362:564-565, Echaniz-Laguna,A.,et al, 2010
Zonisamide Discontinuation Due to Psychiatric and Cognitive Adverse Events: A Case-Control Study
Neurol 75:513-518, White,J.R., et al, 2010
What if the sexual headache is not a joke?
BJMP 3:304-308, Redelman, M., 2010
Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009
A Systematic Review of Antiepilpetic Drug Initiation and Withdrawal
The Neurologist 15:122-131, Shih,J.J &Ochoa,J.G., 2009
Postwithdrawal Rebound Increase in T2 Lesional Activity in Natalizumab-Treated MS Patients
Neurol 70:1150-1151,1073, Vellinga,M.M.,et al, 2008
Initial Management of Epilepsy
NEJM 359:166-176, French,J.A. &Pedley,T.A., 2008
The Clinical and Radiological Spectrum of Reversible Cerebral Vasoconstriction Syndrome. A Prospective Series of 67 Patients
Brain 130:3091-3101, Ducros, A.,et al, 2007
Chronic Daily Headache
NEJM 354:158-165, Dodick,D.W., 2006
Adult Epilepsy
Lancet 367:1087-1100, Duncan,J.S.,et al, 2006
Medication-Overuse Headache in Patients With Cluster Headache
Neurol 67:109-113, Paemeleire,K.,et al, 2006
The Serotonin Syndrome
NEMJ 352:1112-20, Boyer, E.W. & Shannon, M., 2005
Transient Lesion in the Splenium of the Corpus Callosum and Antiepileptic Drug Withdrawal
Neurol 65:1032-1036, Gurtler,S.,et al, 2005
Intrathecal Baclofen for Stiff-Person Syndrome: Life-Threatening Intermittent Catheter Leakage
Neurol 60:1976-1978, Bardutzky,J.,et al, 2003
Intrathecal Baclofen Withdrawal Mimicking Sepsis
J Emerg Med 24:423-427, Kao,L.W.,e tal, 2003
Dose-Related Neurocognitive Effects of Marijuana Use
Neurol 59:1337-1343,1295, Bolla,K.I.,et al, 2002
Clinical Features of Withdrawal Headache Following Overuse of Triptans and Other Headache Drugs
Neurol 57:1694-1698, Katsarava,Z.,et al, 2001
Management of Epilepsy in Adolescents and Adults
Lancet 356:323-329, Brodie,M.J. & French,J.A., 2000
Safety of Discontinuation of Anticoagulation in Patients with Intracranial Hemorrhage at High Thromboembolic Risk
Arch Neurol 57:1710-1713,1682, Phan,T.G.,et al, 2000
Medical Management of Epilepsy in Adults
Neurol 51:S15-S20, Mattson,R.H., 1999
Acute Delirium After Withdrawal of Amantadine in Parkinson's Disease
Neurol 50:1456-1458, Factor,S.A.,et al, 1998
Medical Causes of Seizures
Lancet 352:383-390, Delanty,N.,et al, 1998
Trihexyphenidyl Withdrawal Encephalopathy
Ann Neurol 41:133-134, Johkura,K.,et al, 1997
Antiepileptic Drugs
NEJM 334:168-175, Brodie,M.J.&Dichter,M.A., 1996
Easy Therapeutical Management of Sumatriptan-Induced Daily Headache
Neurol 47:297-298, Gobel,H.,et al, 1996
Status Epilepticus Induced by Felbatol Withdrawal
Neurol 45:1021-1022, DeGiorgio,C.M.,et al, 1995
Chronic headache:Appropriate Use of Opiate Analgesics
Neurol 44:S18-S24, Markley,H.G., 1994
Epilepsy
JNNP 57:264-277, Chadwick,D., 1994